Case | Age (y) | Visual in-person trained | Agreement | Visual e-trained | Agreement | Quantification | SUVR | PET evaluation | Histopathology (BSS + IHC) | Clinical diagnosis |
3 | 82 | Positive | 100% | Positive | 100% | Negative | 1.01 | Marked atrophy | Positive | AD |
5 | 90 | Positive | 100% | Positive | 100% | Negative | 1.02 | Marked atrophy | Positive | AD |
39 | 82 | Positive | 100% | Positive | 100% | Negative | 1.42 | Marked atrophy | Positive | AD |
40 | 70 | Positive | 100% | Positive | 100% | Negative | 1.14 | — | Positive | Other dementia |
43 | 92 | Positive | 100% | Positive | 80% | Negative | 1.18 | Marked atrophy | Positive | AD |
44 | 72 | Positive | 100% | Positive | 100% | Negative | 1.14 | Marked atrophy | Positive | AD |
45 | 91 | Positive | 100% | Positive | 100% | Negative | 1.45 | Marked atrophy | Positive | AD |
75 | 81 | Negative | 67% | Positive | 80% | Negative | 1.17 | — | Negative | AD |
22 | 98 | Negative | 67% | Negative | 80% | Positive | 1.67 | — | Positive | AD |
67 | 83 | Negative | 100% | Negative | 80% | Positive | 1.52 | Marked atrophy | Negative | Other dementia |
↵* Discordant cases are those visually interpreted as positive but quantified as negative or visually interpreted as negative and quantified as positive.
Agreement = Interinterpreter agreement within training group; PET evaluation = additional PET assessment conducted after initial study; IHC = immunohistochemistry.